Additive Manufacturing of 17-4PH Alloy: Tailoring the Printing Orientation for Enhanced Aerospace Application Performance

Additive manufacturing (AM) is one of the fastest-growing markets of our time. During its journey in the past 30 years, its key to success has been that it can easily produce extremely complex shapes and is not limited by tooling problems when a change in geometry is desired. This flexibility leads to possible solutions for creating lightweight structural elements while keeping the mechanical properties at a stable reserve factor value. In the aerospace industry, several kinds of structural elements for fuselage and wing parts are made from different kinds of steel alloys, such as 17-4PH stainless steel, which are usually milled from a block material made using conventional processing (CP) methods. However, these approaches are limited when a relatively small element must withstand greater forces that can occur during flight. AM can bridge this problem with a new perspective, mainly using thin walls and complex shapes while maintaining the ideal sizes. The downside of the elements made using AM is that the quality of the final product is highly dependent on the build/printing orientation, an issue extensively studied and addressed by researchers in the field. During flight, some components may experience forces that predominantly act in a single direction. With this in mind, we created samples with the desired orientation to maximize material properties in a specific direction. The goal of this study was to demonstrate that an additively manufactured part, produced using laser powder bed fusion (LPBF), with a desired build orientation has exceptional properties compared to parts produced via conventional methods. To assess the impact of the build orientation on the LPBF parts’ properties, one-dimensional tensile and dynamic fracture toughness tests were deployed

A Novel Process to Produce Ti Parts from Powder Metallurgy with Advanced Properties for Aeronautical Applications

Titanium and its alloys have excellent corrosion resistance, heat, and fatigue tolerance, and their strength-to-weight ratio is one of the highest among metals. This combination of properties makes them ideal for aerospace applications; however, high manufacturing costs hinder their widespread use compared to other metals such as aluminum alloys and steels. Powder metallurgy (PM) is a greener and more cost and energy-efficient method for the production of near-net-shape parts compared to traditional ingot metallurgy, especially for titanium parts. In addition, it allows us to synthesize special microstructures, which result in outstanding mechanical properties without the need for alloying elements. The most commonly used Ti alloy is the Ti6Al4V grade 5. This workhorse alloy ensures outstanding mechanical properties, demonstrating a strength which is at least twice that of commercially pure titanium (CP-Ti) grade 2 and comparable to the strength of hardened stainless steels. In the present research, different mixtures of both milled and unmilled Cp-Ti grade 2 powder were utilized using the PM method, aiming to synthesize samples with high mechanical properties comparable to those of high-strength alloys such as Ti6Al4V. The results showed that the fine nanoparticles significantly enhanced the strength of the material, while in several cases the material exceeded the values of the Ti6Al4V alloy. The produced sample exhibited a maximum compressive yield strength (1492 MPa), contained 10 wt.% of fine (milled) particles (average particle size: 3 μm) and was sintered at 900 °C for one hour

Additional file 1: of Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study

STROBE Statement—checklist of items that should be included in reports of observational studies

Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis

Objectives Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS. Patients and methods Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months. Results TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP. Conclusions Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS

Associations of vascular and bone status in arthritis patients

Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Bone and vascular markers were previously assessed by ELISA. Bone density was measured by DXA and quantitative CT (QCT). Flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) were assessed by ultrasound. Multiple correlation analyses indicated associations between bone and vascular markers. Osteoprotegerin, sclerostin and cathepsin K were significantly associated with FMD, IMT and PWV, respectively (p < 0.05). Moreover, total and trabecular BMD determined by QCT inversely correlated with IMT (p < 0.05). On the other hand, among vascular parameters, platelet-derived growth factor BB and IMT correlated with DXA femoral and QCT total BMD, respectively (p < 0.05). In the RM-ANOVA analysis, anti-TNF treatment together with baseline osteocalcin, procollagen 1 N-terminal propeptide (P1NP) or vitamin D3 levels determined one-year changes in IMT (p < 0.05). In the MANOVA analysis, baseline disease activity indices (DAS28, BASDAI), the one-year changes in these indices, as well as CRP exerted effects on multiple correlations between bone and vascular markers (p < 0.05). As the pattern of interactions between bone and vascular biomarkers differed between baseline and after 12 months, anti-TNF therapy influenced these associations. We found a great number of correlations in our RA and AS patients undergoing anti-TNF therapy. Some of the bone markers have been associated with vascular pathophysiology, while some vascular markers correlated with bone status. In arthritis, systemic inflammation and disease activity may drive both vascular and bone disease

Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients

Introduction Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. There have not been many peripheral quantitative computed tomography (QCT) studies in patients receiving biologics. We assessed volumetric and areal bone mineral density (BMD) by forearm QCT and dual-energy X-ray absorptiometry (DXA), respectively in addition to laboratory biomarkers in these arthritides. Methods Forty RA and AS patients treated with either etanercept (ETN) or certolizumab pegol (CZP) were undergoing follow-ups for one year. Volumetric and areal BMD, as well as parathyroid hormone (PTH), osteocalcin, RANKL, 25-hydroxyvitamin D (VITD), P1NP, CTX, sclerostin (SOST), Dickkopf 1 (DKK-1) and cathepsin K (CATHK) were determined. Results We did not observe any further bone loss during the 12-month treatment period. Volumetric and areal BMD showed significant correlations with each other (p<0.017 after Bonferroni's correction). Trabecular QCT BMD at baseline (p=0.015) and cortical QCT BMD after 12 months (p=0.005) were inversely determined by disease activity at baseline in the full cohort. Trabecular QCT BMD at baseline also correlated with CTX (p=0.011). In RA, CRP negatively (p=0.014), while SOST positively (p=0.013) correlated with different QCT parameters. In AS, RANKL at baseline (p=0.014) and after 12 months (p=0.007) correlated with cortical QCT BMD. In the full cohort, 12-month change in QTRABBMD was related to TNF inhibition together with elevated VITD-0 levels (p=0.031). Treatment and lower CATHK correlated with QCORTBMD changes (p=0.006). In RA, TNF inhibition together with VITD-0 (p<0.01) or CATHK-0 (p=0.002), while in AS, treatment and RANKL-0 (p<0.05) determined one-year changes in QCT BMD. Conclusions BMD as determined by QCT did not change over one year of anti-TNF treatment. Disease activity, CATHK, RANKL and VITD may be associated with the effects of anti-TNF treatment on QCT BMD changes. RA and AS may differ in this respect